openPR Logo
Press release

Antibody Drug Conjugate Market Sales Revenue Opportunity Report

07-04-2017 07:13 AM CET | Health & Medicine

Press release from: Kuick Resarch

Antibody Drug Conjugate Market Sales Revenue Opportunity

Ever since the first attempt in the 1980's to use antibody-based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates (ADC) is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the future in terms of targeted accumulation of drug in the tumor cell or tissue.

Download Report:

https://www.kuickresearch.com/report-Antibody-Drug-Conjugate-Market-Opportunity-Analysis.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

" Antibody Drug Conjugate Market Opportunity Analysis" Table of Contents

1. Introduction to Antibody Drug Conjugate

2. Antibody Drug Conjugate Mechanism
2.1 Components of Antibody Drug Conjugate
2.2 Mechanism of Antibody Drug Conjugate

3. Why Need for Antibody Drug Conjugate?

4. Antibody Drug Conjugate Market Outlook
4.1 Market Overview
4.2 Anti Drug Conjugate Clinical Pipeline Analysis

5. Antibody Drug Conjugate Market Dynamics
5.1 Market Acceptability Drivers
5.2 Issues to be Addressed
5.3 Future Growth Opportunities

6. Antibody Drug Conjugate Clinical Trial Insight by Phase & Target Indications
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
6.7 Phase III

7. Marketed Antibody Drug Conjugate

8. Competitive Landscape
8.1 ADC Therapeutics
8.2 Agensys
8.3 Ambrx
8.4 Amgen
8.5 AREVA Med
8.6 Bayer HealthCare
8.7 Genentech
8.8 Immunomedics
8.9 ImmunoGen
8.10 Seattle Genetics

Figure 2-1: Components of Antibody Drug Conjugate
Figure 2-2: Mechanism of Antibody Drug Conjugate
Figure 4-1: Global Antibody Drug Conjugate Market (US$ Billion), 2013-2020
Figure 4-2: Global Adcetris Sales (Million US$), 2013 & 2020
Figure 4-3: Adcetris Sales in US & Europe (Million US$), 2013
Figure 4-4: Global Kadcyla Sales (Million US$), 2013 & 2020
Figure 4-5: Kadcyla Market in US & Ex US (Million US$), 2013
Figure 4-6: Antibody Drug Conjugate Clinical Pipeline by Phase (%)
Figure 4-7: Antibody Drug Conjugate Clinical Pipeline by Phase (%)

List of Tables

Table 8-1: ADC Therapeutics Clinical Pipeline
Table 8-2: Agensys Clinical Pipeline
Table 8-3: Ambrx Clinical Pipeline
Table 8-4: Amgen Clinical Pipeline
Table 8-5: AREVA Med Clincal Pipeline
Table 8-6: Genentech Clinical Pipeline
Table 8-7: Immunomedics Clinical Pipeline
Table 8-8: ImmunoGen Clinical Pipeline
Table 8-9: Seattle Genetics Clinical Pipeline
Need custom market research solution? We can help you with that too

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

+91-11-47067990eeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antibody Drug Conjugate Market Sales Revenue Opportunity Report here

News-ID: 606837 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug